OPUS-1: what matters beyond management’s PCV base case

 Vaxcyte’s pivotal OPUS-1 readout by the end of October is not a simple 31/31 pass/fail event. Management has already framed several expected serotype misses, so the stock debate is whether VAX-31 can deliver a meaningfully better-than-guided profile versus merely protecting adult value already embedded in PCVX’s valuation. Our latest report focuses on where the readout could surprise positively or negatively, how likely those outcomes are, how much they matter commercially, and how far the adult readout should be read through to the paediatric opportunity.

Our latest PCVX report addresses four key investor questions:

• Which elements of the serotype-level profile are most likely to drive upside or downside versus management expectations?

• What would need to happen in OPUS-1 to support a meaningful re-rating of PCVX rather than simply protect value already embedded in the shares?

• How much should the adult OPUS-1 result change investors’ confidence in the longer-term paediatric opportunity?

• What is the likelihood that the key serotypes beat or miss management’s expectations in OPUS-1, and how competitively meaningful would those outcomes be?